Fumarates and Cancer
Accumulation of intermediate metabolites of the tricarboxylic acid (TCA) cycle in tumor cells can cause epithelial-to-mesenchymal transition (EMT), although the exact mechanisms remain elusive. Recent studies show that the oncometabolite fumarate, which accumulates in fumarate hydratase-deficient renal cancers, confers tumor aggressiveness by causing epigenetic changes in the antimetastatic miRNA cluster mir-200ba429. This may have important implications for the use of fumarates in the clinic.
|Keywords||cancer, epithelial-to-mesenchymal transition, fumarate, metastasis|
|Persistent URL||dx.doi.org/10.1016/j.molmed.2016.12.001, hdl.handle.net/1765/95178|
|Journal||Trends in Molecular Medicine|
Fuhler, G.M, Eppinga, H, & Peppelenbosch, M.P. (2017). Fumarates and Cancer. Trends in Molecular Medicine, 23(1), 3–5. doi:10.1016/j.molmed.2016.12.001